30th week of 2022 patent applcation highlights part 8 |
Patent application number | Title | Published |
20220233450 | COMPOSITIONS OF FILM COATINGS FOR TABLETS WITH INCREASED GLOSS, METHOD FOR PRODUCTION THEREOF AND APPLICATION OF SAME - Compositions and procedures for applying pharmaceutical tablet coatings, recognized as film coating wherein it is possible to obtain a final product coated with brightness superior to that achievable with typical compositions. The main difference in the composition is in the inclusion of the product derived from isomaltulose, which is a mixture of 6-O-α-D-glucopyranosyl-D-mannitol dihydrate with 6-O-α-D-glucopyranosyl-D-sorbitol, known as Isomalt, combined with a variety of film-forming polymers such as ethylene glycol and polyvinyl alcohol copolymer, copovidone, polyvinyl alcohol, and cellulosic derivatives, wherein the process conditions are advantageous as it is possible to handle high concentrations of solids in their preparation and wider applying temperature ranges than normally recommended for film coatings. | 2022-07-28 |
20220233451 | EDIBLE IJ INK, TABLET, AND CAPSULE - An edible IJ ink that has good dispersion stability and printing resumability (intermission resumability), dries quickly, and provides good print quality (for example, prevents streaking), and to provide a tablet and a capsule including a printed part printed using the edible IJ ink, the edible IJ ink comprises water, titanium oxide, a dispersant, a wetting agent, and a water-soluble polysaccharide having a weight average molecular weight smaller than 10,000, and the dispersant includes at least one of sodium carboxymethyl cellulose, sodium alginate, and sodium carbonate. | 2022-07-28 |
20220233452 | MINI SOFTGEL NAPROXEN COMPOSITION - Disclosed herein are mini softgel capsules comprising a reaction product of naproxen free acid and potassium hydroxide in a molar ratio of potassium hydroxide to naproxen free acid of less than about 1. Also disclosed herein are methods for treating patients in need thereof with the mini softgel capsules as well as methods for stabilizing mini softgel capsules that include a fill composition that has a high concentration of active agent. | 2022-07-28 |
20220233453 | CAPSULE FORMULATIONS - The present disclosure provides solid solution capsule formulations of Compound 1 | 2022-07-28 |
20220233454 | TUNABLE DEGRADATION IN HYDROGEL MICROPARTICLES - Non-alginate hydrogel microparticles for localized delivery and sustained release of therapeutic cells and/or tissues (including homogenous or heterogenous cell clusters) at a site of implantation. The microparticles comprise a 3-dimensional matrix of covalently crosslinked non-alginate polymer compounds and a therapeutically-effective amount of cells and/or tissue entrapped therein, wherein the cells have a viability of at least about 50%, and wherein the microparticle has a size of greater than about 30 pm. Compositions containing such microparticles and methods of using such microparticles for treatment are also described. | 2022-07-28 |
20220233455 | POLYMER-LIPID NANOCOMPLEX FOR ENHANCED AQUEOUS SOLUBILISATION AND ABSORPTION OF HYDROPHOBIC ACTIVE COMPOUNDS - The current invention relates to a polymer-lipid nanocomplex for enhanced aqueous solubilisation and absorption of hydrophobic active compounds, a process for producing such a nanocomplex, and to methods of use of such a nanocomplex. | 2022-07-28 |
20220233456 | METHODS AND COMPOSITIONS PARTICULARLY FOR TREATMENT OF ATTENTION DEFICIT DISORDER - There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described. | 2022-07-28 |
20220233457 | COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING CEREBROVASCULAR DISEASE COMPRISING MELITTIN OR MAGNETIC IRON OXIDE NANOPARTICLE LOADED WITH MELITTIN AS EFFECTIVE COMPONENT - A method for treating a cerebrovascular disease according to an embodiment of the present disclosure includes administering a composition comprising at least one of melittin and magnetic iron oxide nanoparticle loaded with melittin as an effective component to a subject in need thereof. A composition according to an embodiment of the present disclosure for preventing, ameliorating, or treating a cerebrovascular disease includes melittin or magnetic iron oxide nanoparticle loaded with melittin as an effective component. The melittin or magnetic iron oxide nanoparticle loaded with melittin not only can reduce the diameter of cerebral arteries, increase the thickness of cerebral arteries, increase the content of elastin and smooth muscles, and reduce the content of abnormal collagen but also has an effect of suppressing the expression of the factors which mediate an inflammatory response. | 2022-07-28 |
20220233458 | Complex of Noble Metal Oxide Nanoparticles and Tellurium Nanowires and Biomedical Applications Thereof - Green-synthesized tellurium nanowires (GREEN-TeNWs) are generated using a biopolymer as a unique reducing agent, purified, and used as a template for the growth of coated palladium nanoparticles (PdNPs) and platinum nanoparticles (PtNPs) on top of the GREEN-TeNWs, in a reaction that can take place in seconds, with no need for high temperature, stirring, or for additional reducing agent. The heterogeneous structure can contain palladium oxide or platinum oxide. The green-synthesized PdNPs-TeNWs (palladium nanoparticles with tellurium nanowires) and PtNPs-TeNWs (platinum nanoparticles with tellurium nanowires) show potential biomedical applications as antibacterial, anticancer, and antioxidant agents, and show low cytotoxicity for healthy human cells. | 2022-07-28 |
20220233459 | ANALYSIS OF MATERIALS FOR TISSUE DELIVERY - Described herein are compositions and methods for identifying materials suitable for delivery of an agent to a target tissue. These compositions and methods may simultaneously screen a library of materials for the ability to deliver an agent to a target. The compositions and methods may also be used to confirm that the agent is delivered in a manner sufficient for function of the agent. | 2022-07-28 |
20220233460 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS - The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid. | 2022-07-28 |
20220233461 | ACTIVE SUBSTANCE DELIVERY SYSTEM - The present invention relates to an active substance delivery system, preferably an anti-cancer agent delivery system, comprising one or more active substances included in nanoparticles and a method for producing such a delivery system. | 2022-07-28 |
20220233462 | BIODEGRADABLE MULTILAYER NANOCAPSULES FOR THE DELIVERY OF BIOLOGICALLY ACTIVE AGENTS IN TARGET CELLS - The present invention relates to a biodegradable multilayer nanocapsule for the delivery of at least one biologically active agent into at least one target cell consisting of at least two layers of at least two biodegradable polymers which are laid one onto the other and whereby the biologically active agent is layered onto a layer of a biodegradable polymer and covered with a further layer of a biodegradable polymer, whereby one biologically active agent is a nucleic acid. | 2022-07-28 |
20220233463 | LOCAL ANESTHETIC COMPRISING A TRP CHANNEL MODULATOR - Provided are methods and compositions for reducing a throat irritation caused by inhaling vapors or particles of at least one material selected from the group consisting of cannabis, cannabinoids, tobaccO, a herb or combinations thereof, the method comprising administering to a subject in need thereof at least one transient receptor potential (TRP) channel modulator prior to or simultaneously with said inhaling said vapors or particles of said at least one material. Further provided are methods and compositions comprising at least one TRP channel agonist, and/or at least one TRP channel partial agonist for treating pain-selective analgesia via TRP channels; methods for treating local pain; methods for treating migraine and symptoms thereof; and methods for treating osteoporosis and symptoms thereof. | 2022-07-28 |
20220233464 | CANNABIDIOL INFUSED FOAM ELEMENT OR SURFACE - A method of making a cannabidiol infused foam element is disclosed wherein the cannabidiol infused foam element comprises cannabidiol and foam, wherein the foam comprises polyurethane foam, viscoelastic foam, latex foam, or combinations thereof, wherein the cannabidiol infused foam element has a plurality of layers of foam material, and wherein the foam material also comprises the cannabidiol (e.g., in the form of an oil, a powder, or combinations thereof). | 2022-07-28 |
20220233465 | CANNABINOID-COMPRISING COMPOSITIONS FOR MANAGEMENT OF PAIN - There are provided compositions comprising a purified cannabidiol (CBD) or a derivative thereof and an anti-inflammatory botanical extract, and methods of use thereof for the management of pain in a subject. | 2022-07-28 |
20220233466 | TERAMEPROCOL AND NORDIHYDROGUAIARETIC ACID (NDGA) DERIVATIVES AS CORONAVIRUS ANTI-VIRAL AGENTS - Nordihydroguaiaretic acid (NDGA) derivatives, including terameprocol (TMP) have utility as anti-viral agents for use on patients infected with or at risk of infection with a coronavirus, including SARS-CoV-2. In vitro studies show coronavirus-infected cells treated with 0.2 μM-20 μM TMP show reduced viral RNA activity in vitro. Treatment-related cytotoxicity is not shown at 0.2 μM TMP with a low percentage of cytotoxicity shown at 5 μM TMP. In application, the NDGA derivatives may be administered to a patient intravenously at a molar concentration of 0.1-50 μM or orally at a molar concentration of 0.1-100 μM. | 2022-07-28 |
20220233467 | Composition, System and Method for a Pig Contraceptive - An orally ingestible contraceptive composition for a pig is provided. The exemplary composition comprises 0.005 to 1.4 wt. % free gossypol and non-free-gossypol matter. The non-free-gossypol matter comprises a bulk feed component, a pig attractant, a flavored component or any combination thereof. In a second aspect, an assembly is provided. The assembly comprises an orally ingestible contraceptive composition for a pig and a package. In a third aspect, a system for delivering an orally ingestible contraceptive composition to a pig is provided. The system comprises the composition and an apparatus. The apparatus is configured to permit pigs to eat the composition and inhibit other animals from eating the composition. In a fourth aspect, a method is provided for delivering an orally ingestible contraceptive composition to a pig. The method comprises making the composition available to the pig. | 2022-07-28 |
20220233468 | METHODS FOR TREATING CORONAVIRUS INFECTION - The present invention provides methods for treating or preventing coronavirus infection, or a coronavirus-associated disease, condition, or symptom in a subject. In particular, the methods comprise administering a transmembrane protease serine 2 (TMPRSS2) inhibitor, or a pharmaceutically acceptable salt or tautomer thereof. | 2022-07-28 |
20220233469 | METHODS, COMPOSITIONS AND DEVICES FOR TREATING NEUROINFLAMMATORY CONDITIONS - The present disclosure relates to methods, compositions and devices for treating neuroinflammatory conditions in female subjects. In certain embodiments, the present disclosure provides a method of treating a female subject suffering from, or susceptible to, a neuroinflammatory condition, the method comprising intrauterine administration to the subject of an effective amount of an agent that reduces activation of the innate immune system and thereby treating the subject. | 2022-07-28 |
20220233470 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2022-07-28 |
20220233471 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT - Systems and methods of delivering a drug product by inhalation can include a prodrug composition. | 2022-07-28 |
20220233472 | VETERINARY BROMHEXINE HYDROCHLORIDE SOLUBLE POWDER, PREPARATION METHOD AND USE THEREOF - A veterinary bromhexine hydrochloride soluble powder, a preparation method and use thereof are disclosed. The method includes: (1) weighing a prescription amount of bromhexine hydrochloride and a part of prescription amount of citric acid, performing a primary mixing, pulverizing, sieving and dividing the mixed material into three equal parts; (2) weighing a remaining prescription amount of citric acid, pulverizing, sieving and dividing it into three equal parts; (3) weighing a prescription amount of lactose, sieving, and weighing three parts of the lactose accounting for 10% of the total amount; (4) putting one part of the mixed material obtained in “1”, one part of citric acid obtained in “2” and one part of lactose obtained in “3” alternately into a multi-directional motion mixer; (5) notifying an QA to inspect semi-finished products; and (6) packaging qualified semi-finished products, and warehousing qualified finished products. | 2022-07-28 |
20220233473 | INJECTABLE SOLUTION OF NOREPINEPHRINE - A ready-to-administer stable injectable norepinephrine solution comprising water, norepinephrine, and a tonicity agent. The solution has a pH from 3.7 to 4.3 and is substantially free of chelating agents and antioxidants. | 2022-07-28 |
20220233474 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2022-07-28 |
20220233475 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE - The present invention provides a method of inhibiting, suppressing or preventing levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of inhibiting, suppressing or preventing Parkinson's Disease in a patient, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention. | 2022-07-28 |
20220233476 | IRON SUPPLEMENT - An orally deliverable dosage system comprises (a) iron in a form of one or more physiologically acceptable iron grades, compounds and/or complexes; and (b) an agent to mitigate one or more gastrointestinal adverse effects of unabsorbed iron, said agent comprising one or both of a zinc component and a chelator component, said zinc component if present comprising one or more physiologically acceptable zinc compounds and/or complexes, and said chelator component if present comprising an ion-chelating compound formulated for release distal to the primary site of iron absorption in the duodenum. | 2022-07-28 |
20220233477 | METHODS OF GENERATING OLIGODENDROCYTES - A method of generating human mature oligodendrocytes is disclosed. The method comprises contacting a cell population which comprises human pre-oligodendrocytes with an inhibitor of the MAPK/ERK pathway under conditions that allow the pre-oligodendrocytes to differentiate into mature oligodendrocytes. Use of the MAPK/ERK pathway inhibitor for treating diseases is also disclosed. | 2022-07-28 |
20220233478 | PHARMACEUTICAL COMPOSITION CONTAINING HYDROXYUREA FOR USE IN THE TREATMENT OF SEVERE CHRONIC ANEMIA - The invention relates to a pharmaceutical composition containing hydroxyurea, for the treatment of severe chronic anemia in a patient suffering from sickle cell anemia not already undergoing treatment with hydroxyurea and not suffering a vaso-occlusive crisis. | 2022-07-28 |
20220233479 | COMPOSITIONS FOR TREATMENT OF SUBSTANCE USE DISORDER - Certain embodiments are directed to methods of treating or preventing an addictive behavior in a subject, said method comprising administering to said subject an effective amount of a DMTU or a composition comprising same. | 2022-07-28 |
20220233480 | USE OF ANGIOTENSIN II TYPE 2 RECEPTOR AGONIST - There is provided N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-sulfonamide, or a pharmaceutically-acceptable salt thereof, for use in a method of treatment of respiratory virus-induced tissue damage. Such damage may be caused by coronaviruses, including severe acute respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus. N-Butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide alleviates symptoms of diseases caused by those viruses (including coronavirus disease 2019 or COVID-19), such as cough, dyspnea, pneumonia, respiratory distress, respiratory failure and/or fibrosis of organs such as the lungs, the heart or the kidneys, and may thus prevent respiratory virus-induced morbidity and/or mortality. In particular, it has been found in a clinical study that the proportion of patients with COVID-19 needing oxygen treatment was significantly lower for patients that were administered N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide compared to placebo. | 2022-07-28 |
20220233482 | METHOD, COMPOSITION AND PACKAGE FOR BOWEL CLEANSING - The present invention provides a highly palatable colon cleansing formulation that utilizes a low chloride electrolyte-replenishing base solution. When formulated with polyethylene glycol and a selected sugar alcohol, the formulation offers the advantages of superior palatability without undesirable concomitant side effects or a decrease in cleansing efficacy. | 2022-07-28 |
20220233483 | ORAL BACLOFEN SOLUTIONS - The present disclosure relates to aqueous oral solutions comprising baclofen. In one embodiment, the aqueous oral solutions comprise a buffer comprising citric acid, a salt of citric acid, or any combination thereof, and are stored at from about 2° C. to about 8° C. The present disclosure also relates to buffer free aqueous oral solutions comprising baclofen. Additionally, the present disclosure relates to an assay for determining the amount of an impurity, 4-(3-carboxymethyl)-3-hydroxy-2,5-dioxopyrrolidin-1-yl)-3-(4-chlorophenyl)butanoic acid, in a baclofen containing solution, and to methods of treatment using such aqueous oral solutions. | 2022-07-28 |
20220233484 | SYNERGISTIC NUTRITIONAL COMPOSITIONS FOR TREATING NEUROCOGNITIVE DISORDERS - The invention disclosed herein related to novel synergistic nutritional compositions for treating neurocognitive disorders. Particularly, the invention provides stable nutritional composition for treating neurocognitive disorders comprising exogenous blend of magnesium L-threonate and homotaurine present in the weight ratio of 1:0.1 to 1:1, along with pharmaceutically acceptable excipients. Further, the present synergistic nutritional composition is useful for treating neurocognitive disorders such as Alzheimer's disease (AD); dementia; Attention-deficit/hyperactivity disorder and like thereof. | 2022-07-28 |
20220233485 | COMPOSITION FOR TREATING ATOPY OR PRURITUS COMPRISING N-ACETYL OR N-ACYL AMINO ACID - The present disclosure relates to a composition for preventing, alleviating or treating pruritus and/or atopy using an N-acetylamino acid or an N-acylamino acid having almost no side effects on the human body. Also, the present disclosure relates to a cosmetic composition for moisturizing skin or soothing skin. The composition of the present disclosure may be utilized to ameliorate a problematic skin condition caused by various causes, or to safely and effectively alleviate or treat pruritus and/or atopy without concern about side effects. | 2022-07-28 |
20220233486 | RESPIRATORY TRACT DELIVERY OF LEVODOPA AND DOPA DECARBOXYLASE INHIBITOR FOR TREATMENT OF PARKINSON'S DISEASE - A dry pharmaceutical composition is provided that is suitable for respiratory tract delivery of levodopa and DDI for treatment of Parkinson's disease or Parkinson syndrome. The dry pharmaceutical composition comprises levodopa, a dopa decarboxylase inhibitor (DDI) and at least one excipient. A unit dosage form of the dry pharmaceutical composition and a method of treating a patient with Parkinson's disease or Parkinson syndrome by administering the dry pharmaceutical composition are also provided. | 2022-07-28 |
20220233487 | PREPARATION FOR USE IN WEIGHT MANAGEMENT COMPRISING OMEGA-3 FATTY ACID SALTS AND BASIC AMINO ACIDS - The present invention is directed to preparation comprising at least one a salt made up from fatty acids containing at least one omega-3 fatty acid and basic amino acids for use in stimulating an increased secretion of satiety hormones in a subject. | 2022-07-28 |
20220233488 | VERY LONG CHAIN FATTY ACIDS FOR TREATMENT AND ALLEVIATION OF DISEASES - The present invention relates to methods and compositions for treatment and alleviation of diseases. Particularly, the invention provides compositions comprising very long chain fatty acids for use in treatment, such as of subjects having a deficient or abnormal level of VLCFAs present in specific tissue which play a role in the disease. Particularly, the invention provides methods and compositions for treatment of subjects having a reduced ability for endogenic synthesis of fatty acids. | 2022-07-28 |
20220233489 | KITS FOR DERMAL CARE - Compositions and methods for treating administering retinoid or retinoid-related compounds without side effects. | 2022-07-28 |
20220233490 | COMPOSITIONS AND METHODS FOR SKIN REJUVENATION - The present invention relates to the field of skin rejuvenation. Specifically, the present invention provides compositions and methods for promoting skin rejuvenation using a toll-like receptor 3 (TLR3) agonist and retinoic acid or derivatives thereof. In a specific embodiment, a method for treating wrinkles in a subject comprises the steps of (a) administering to the area of the subject comprising a wrinkle a composition comprising an effective amount of retinoic acid or a derivative thereof; and administering to the area of the subject comprising a wrinkle a composition comprising an effective amount of a TLR3 agonist. | 2022-07-28 |
20220233491 | BISMUTH-THIOL COMPOSITIONS AND METHODS FOR TREATING WOUNDS - The invention relates to bismuth-thiol compounds and pharmaceutical preparations thereof. The invention further relates to methods for treating a topical wound, comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising a bismuth-thiol compound, wherein the composition is applied to the infection. Methods for treating microbial infections such as diabetic foot infections are also provided. | 2022-07-28 |
20220233492 | METHOD OF PREVENTING OR TREATING POSTOPERATIVE PAIN - A method for treating or preempting pain including postoperative pain following a soft or hard tissue surgery is disclosed. Also disclosed is a method for reducing an postoperative analgesic need, including administering a compound of Formula (I) or a salt thereof. | 2022-07-28 |
20220233493 | SYSTEM AND METHOD FOR CANNABINOID OIL EMULSIFICATION - Disclosed herein is a system and method for emulsifying cannabinoid oil. According to one embodiment the method comprises mixing cannabinoid oil and a surfactant; heating the distillate; heating distilled water; heating the surfactant; mixing oil with the water; starting the first of two consecutive runs through a high pressure homogenizer system; adding a gumming agent; blending the new mixture; adding lactic acid compound; adding glycerin; blending again; letting the mixture stand; and blending again, thereby producing emulsified cannabinoid oil. | 2022-07-28 |
20220233494 | ANTIBIOTIC CANNABINOID-TERPENE FORMULATIONS - Pharmaceutical formulations are provided that include at least two antibiotically active ingredients: a cannabinoid that is one or more of cannabichromene (CBC), cannabidiol (CBD) and/or cannabigerol (CBG); a sesquiterpene that is one or both of a-humulene and/or β-caryophyllene; and a lipopeptide antibiotic that is daptomycin or an analogue thereof. The antibiotically active ingredients may be provided in relative amounts that amplify their individual activities, including amounts that are synergistically effective in an assay to inhibit growth and/or reproduction of an | 2022-07-28 |
20220233495 | CANNABINOID FORMULATIONS - The present invention relates to a pharmaceutical formulation containing one or more cannabinoids. Preferably the formulation is a molecular dispersion of one or more cannabinoids in a pH dependent release polymer. Preferably the formulation is able to target delivery of the cannabinoids to specific areas of the digestive system such as the colon or intestines. | 2022-07-28 |
20220233496 | CONJUGATED DEOXYNIVALENOL TO PROTECT AGAINST MYCOTOXICOSIS - The present invention pertains to the use of conjugated deoxynivalenol (DON) in a method to protect an animal against DON induced mycotoxicosis, in particular to protect against a decrease in average daily weight gain, liver damage, stomach ulcers and/or kidney damage as a result of the ingestion of DON. | 2022-07-28 |
20220233497 | CANNABINOID DERIVATIVES AND METHODS FOR THEIR PREPARATION - Novel compounds, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the compounds are agonists and/or ligands of cannabinoid receptors and may be useful, inter alia, for treating and/or preventing pain, gastrointestinal disorders, genitourinary disorders, inflammation, glaucoma, auto-immune diseases, ischemic conditions, immune-related disorders, and neurodegenerative diseases, for providing cardioprotection against ischemic and reperfusion effects, for inducing apoptosis in malignant cells, and as an appetite stimulant. | 2022-07-28 |
20220233498 | METHODS AND COMPOSITIONS FOR TREATING ENDOMETRIOSIS AND ENDOMETRIOSIS ASSOCIATED SYMPTOMS - Methods and compositions are provided for treating endometriosis in an individual, and the pain associated with endometriosis. Aspects of the methods include administering to the individual an agent that promotes ALDH activity. | 2022-07-28 |
20220233499 | MODIFIED PEG-400 - ASCORBIC ACID (mPEG-AA) COMPLEX AND USES THEREOF - The present invention provides a modified PEG-400-ascorbic acid (mPEG-AA complex) comprising the reaction product of fluorescent polyethylene glycol 400 (FLPEG-400) and ascorbic acid. The invention also provides a process for the preparation of the mPEG-AA complex comprising the steps of: (a) heating PEG 400 at a temperature of about 80-90° C. for about 0.5-1 h to get FLPEG-400; (b) adding ascorbic acid to the FLPEG 400; and (c) heating the mixture of FLPEG 400 and ascorbic acid to obtain the mPEG-AA complex. The mPEG-AA complex exhibits both antimicrobial and antiviral activities. | 2022-07-28 |
20220233500 | GLYCOPYRROLATE SALTS - Salts of glycopyrrolate, including solid forms and formulations such as topicals thereof, are disclosed. Methods of making glycopyrrolate salts, including formulations such as topicals thereof, and methods of treating hyperhidrosis with salts of glycopyrrolate, and formulations such as topicals thereof, are disclosed. | 2022-07-28 |
20220233501 | THERAPEUTIC COMBINATIONS - Methods of treatment include administering effective amounts of a nitrogen oxide (NO) donor (such as nicorandil) and a hydrogen sulfide (H | 2022-07-28 |
20220233502 | COMPOSITION FOR PREVENTING OR TREATING ASTHMA, RHINITIS OR CONJUNCTIVITIS, COMPRISING N-ACYL AMINO ACID AS ACTIVE INGREDIENT - The present disclosure relates to a composition for preventing, alleviating or treating asthma, rhinitis and/or conjunctivitis using an N-acylamino acid, which has almost no side effect on the human body. The composition of the present disclosure has an excellent effect of alleviating the symptoms of asthma by exhibiting alleviation effects on both inflammatory response in the airway and airway fibrosis, which are major clinical symptoms of asthma, and thus can be effectively used in drugs or foods for alleviating asthma. In addition, it can be usefully used in drugs or foods for alleviating rhinitis and conjunctivitis since it significantly alleviates the clinical symptoms of rhinitis and conjunctivitis. | 2022-07-28 |
20220233503 | METHODS OF TREATING SEPSIS WITH SYNAPTIC VESICLE 2A AND/OR 2B BINDING CHEMICAL ENTITIES - Methods of treating sepsis induced acute brain dysfunction (SiBD), comprising administering a synaptic vesicle 2a and/or 2b binding chemical entity to a subject with sepsis. Methods of reducing sepsis mortality, comprising administering a synaptic vesicle 2a and/or 2b binding chemical entity to a subject with sepsis. In some embodiments the synaptic vesicle 2a and/or 2b binding chemical entity is a synaptic vesicle 2a and/or 2b modulator such as agonist, partial agonist, antagonist or partial antagonist. In some embodiments the synaptic vesicle 2a and/or 2b binding chemical entity is levetiracetam or a derivative or analogue of levetiracetam. In some embodiments the synaptic vesicle 2a binding chemical entity is levetiracetam. | 2022-07-28 |
20220233504 | PHARMACEUTICAL COMPOSITION COMPRISING LIDOCAINE AND MELATONIN - The present disclosure provides a pharmaceutical composition comprising Lidocaine or salt or hydrates or solvates thereof and Melatonin or salt or hydrates or solvates thereof. The compositions of the present disclosure may find utility in treatment of mucositis, oral mucositis, ulcers, ulcer mediated pain and the like conditions. Aspects of the present disclosure also relates to method of treating oral and gastrointestinal disease/conditions using the advantageous compositions of the present disclosure. | 2022-07-28 |
20220233505 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-[1-(2,3-DIMETHYLPHENYL)ETHYL]-3H-IMIDAZOLE DERIVATIVES FOR TREATING RETINAL DISEASES - The present invention relates to pharmaceutical compositions, containing 4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole, (S) 4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole or (S) [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol, their use as pharmaceuticals for the treatment of retinal diseases, for retinal neuroprotection and vision enhancement. | 2022-07-28 |
20220233506 | FORMULATIONS - Described herein are formulations including pharmaceutical agents comprising ester and/or lactone ring structures, and methods of using the same. The invention is also directed to a method and ophthalmic pharmaceutical compositions including solution and semisolid dosage forms (i.e. ophthalmic creams, gels, lotions, serums, and/or ointments) of treating a patient with various ocular diseases including presbyopia and dry eyes. The method comprising instructing a patient to apply one strip of the ophthalmic composition to the eyelids that includes pilocarpine or other active pharmaceutical ingredients containing ester and/or lactone ring structures with and without the buffering system. | 2022-07-28 |
20220233507 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE - Provided herein are methods of stimulating mitophagy in a subject in need thereof administering to the subject a mitophagy-stimulating amount of a MAS receptor agonist or substance that triggers endogenous production of a MAS receptor agonist. The present disclosure also relates to medical intervention methods and agents, namely methods and agents for stimulation of mitochondrial turnover for treatment of disease in a mammal. The disclosure comprises a method of stimulating increased mitochondrial turnover in a mammal comprising administering to the mammal a pharmacologically suitable dose of a MAS receptor agonist; MAS receptor modulator; a substance that triggers endogenous production of a MAS receptor agonist; a substance that triggers endogenous production of a MAS receptor modulator; or any combination thereof. The pharmacological activity acting on MAS receptor in turn stimulates an increase in mitochondrial turnover in host cells, alleviating a disease state in the host mammalian organism. | 2022-07-28 |
20220233508 | PHARMACEUTICAL COMPOSITION COMPRISING FAMOTIDINE, LIDOCAINE AND MELATONIN - The present disclosure provides a pharmaceutical composition comprising Famotidine or salt or hydrates or solvates thereof, Lidocaine or salt or hydrates or solvates thereof, and Melatonin or salt or hydrates or solvates thereof. The compositions of the present disclosure may find utility in treatment of oral mucositis, gastritis, gastric ulcers and the like conditions. Aspects of the present disclosure also relates to method of treating oral and gastrointestinal diseases/conditions using the advantageous compositions of the present disclosure. | 2022-07-28 |
20220233509 | UNIT ORAL DOSE COMPOSITIONS COMPOSED OF NAPROXEN SODIUM AND FAMOTIDINE FOR THE TREATMENT OF ACUTE PAIN AND THE REDUCTION OF THE SEVERITY AND/OR RISK OF HEARTBURN - Described herein are unit oral dose compositions that reduce the severity of heartburn and/or the risk of the occurrence of heartburn in a human in need of taking naproxen sodium for the OTC treatment of acute pain wherein the human is not experiencing heartburn prior to the oral administration of the unit oral dose composition comprising orally administering to the human of a unit oral dose composition comprising (i) naproxen sodium at a dosage from about 100 mg to about 440 mg per unit oral dose composition and (ii) famotidine at a dosage from about 3 mg to about 20 mg per unit oral dose composition, wherein the dissolution rate of famotidine in the unit oral dose composition in said human at a specified time within 45 minutes of administration of said unit oral dose composition to said human is greater than the dissolution rate of naproxen sodium in the unit oral dose composition in said human at the same specified time. | 2022-07-28 |
20220233510 | UNIT ORAL DOSE COMPOSITIONS COMPOSED OF IBUPROFEN AND FAMOTIDINE FOR THE TREATMENT OF ACUTE PAIN AND THE REDUCTION OF THE SEVERITY AND/OR RISK OF HEARTBURN - Described herein are unit oral dose compositions that reduce the severity of heartburn and/or the risk of the occurrence of heartburn in a human in need of taking ibuprofen for the OTC treatment of acute pain wherein the human is not experiencing heartburn prior to the oral administration of the unit oral dose composition comprising orally administering to the human of a unit oral dose composition comprising (i) ibuprofen at a dosage from about 50 mg to about 400 mg per unit oral dose composition and (ii) famotidine at a dosage from about 3 mg to about 20 mg per unit oral dose composition, wherein the dissolution rate of famotidine in the unit oral dose composition in said human at a specified time within 45 minutes of administration of said unit oral dose composition to said human is greater than the dissolution rate of ibuprofen in the unit oral dose composition in said human at the same specified time. | 2022-07-28 |
20220233511 | METHODS AND COMPOSITIONS FOR TREATMENT OF SMITH KINGSMORE SYNDROME - Methods for alleviating symptoms in a Smith Kingsmore Syndrome (SKS) patient using low doses of a mTOR inhibitor. Also provided herein are methods to determine suitable doses of a mTOR inhibitor for a SKS patient to alleviate at least one symptom associated with SKS with little or no negative impact on behavior features such as the sleep pattern of the SKS patient. | 2022-07-28 |
20220233512 | INHIBITING AN IMMUNE RESPONSE MEDIATED BY ONE OR MORE OF TLR2, RAGE, CCR5, CXCR4 AND CD4 - A method of inhibiting an immune response mediated by one or more of TLR2, RAGE, CCR5, CXR4 and CD4 cell surface receptors of cells in recognized need is disclosed. The method contemplates administering to such cells an effective amount of a of a compound or a pharmaceutically acceptable salt thereof that binds to a pentapeptide of filamin A (FLNA) whose structure is defined within. In one embodiment, the cells to which the compound or its salt is administered exhibit a hyperinflammatory syndrome. | 2022-07-28 |
20220233513 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF - The present invention belongs to the field of medical technology and specifically disclosed is a compound represented by formula (I′), or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and each symbol therein is as defined in the claims. The compound of the present invention may be used as a drug for regulating RET kinase activity or treating RET-related diseases, and has better pharmacokinetic properties. | 2022-07-28 |
20220233514 | PHARMACEUTICAL PREPARATION HAVING EXCELLENT DISSOLUTION PROPERTIES, CONTAINING ESOMEPRAZOLE AND SODIUM BICARBONATE - The present invention relates to a pharmaceutical preparation comprising omeprazole, an enantiomer thereof or a pharmaceutically acceptable salt thereof, and sodium bicarbonate, and a method for preparing the same. Specifically, the present invention relates to a pharmaceutical preparation in which sodium bicarbonate is first disintegrated so as to raise pH, and then omeprazole is dissolved such that the release properties of an active ingredient are improved, and thus the dissolution pattern and bioavailability of a drug can be enhanced. | 2022-07-28 |
20220233515 | Pharmaceutical Composition - The present invention relates to the field of pharmacy, particularly to a pharmaceutical composition for oral administration comprising an (a) inert substrate and a (b) mixture comprising a non-bile acid farnesoid X receptor (FXR) agonist, such as 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder. The present invention also relates to a process for preparing said pharmaceutical composition for oral administration; and to the use of said pharmaceutical composition in the manufacture of a medicament. | 2022-07-28 |
20220233516 | USE OF TIVOZANIB TO TREAT SUBJECTS WITH REFRACTORY CANCER - Disclosed is a method of treating cancer, e.g., refractory cancer, with tivozanib. The methods disclosed include, for example, administering tivozanib as a second or third-line therapy to subjects suffering from refractory advanced renal cell carcinoma where traditional therapies as well as more recent targeted and immune-oncology therapies have not adequately treated the subject. | 2022-07-28 |
20220233518 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2022-07-28 |
20220233519 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2022-07-28 |
20220233520 | Increasing Drug Bioavailability In Naltrexone Therapy - Disclosed are compositions, uses, methods and kits for increasing drug bioavailability in a naltrexone therapy. | 2022-07-28 |
20220233521 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE AND COMBINATION THERAPIES THEREOF - The present invention relates to compounds useful as inhibitors of ATR protein kinase and combination therapies thereof. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. | 2022-07-28 |
20220233522 | CIPROFLOXACIN OTIC COMPOSITION AND KITS AND METHOD FOR USING SAME - Disclosed herein are otic product kits for administration of a sterilized formulation. In some embodiments, the otic product kit comprises: an aseptic container containing the sterilized formulation; a syringe; and an administration needle connectable to the syringe, wherein the sterilized formulation comprising: from about 5.5 wt % to about 6.5 wt % multiparticulate ciprofloxacin; from about 15 wt % to about 17 wt % poloxamer 407; and water. Also disclosed herein are methods of preparing and administrating the sterilized formulation. In some embodiments, the method comprising (1) transferring the sterilized otic formulation from an aseptic container to a syringe through a preparation needle; (2) replacing the preparation needle with an administration needle; and (3) injecting the sterilized otic formulation from the syringe through the administration needle into the ear of a patient. | 2022-07-28 |
20220233523 | ANTIBIOTIC POTENTIATION FOR NONTUBERCULOUS MYCOBACTERIAL DISEASE - The present invention relates to methods and compositions for the treatment of nontuberculous | 2022-07-28 |
20220233524 | LOW-DOSE BRIMONIDINE COMBINATIONS AND USES THEREOF - The present invention is directed to compositions containing low-dose brimonidine and either a second glaucoma drug, an anti-histamine or non-steroidal anti-inflammatory drug. The present invention is further directed to methods of treating glaucoma or allergies or reducing inflammation by administering compositions of the present invention. | 2022-07-28 |
20220233525 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE - Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): | 2022-07-28 |
20220233526 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND DIHYDROPYRIMIDINE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS - Therapeutic combinations of hepatitis B virus (HBV) vaccines and capsid assembly modulators are described. Methods of inducing an immune response against HBV or treating an HBV-induced disease, particularly in individuals having chronic HBV infection, using the disclosed therapeutic combinations are also described. | 2022-07-28 |
20220233527 | METHODS OF TREATING CROHN'S DISEASE AND ULCERATIVE COLITIS - The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor. In certain embodiments, the patient is administered an induction dose of the JAK1 inhibitor to induce clinical remission and/or endoscopic improvement of the Crohn's disease, followed by administration of at least one maintenance dose of the JAK1 inhibitor thereafter. In other embodiments, the present disclosure is directed to methods for treating ulcerative colitis using a JAK1 inhibitor. | 2022-07-28 |
20220233528 | DRY EYE TREATMENTS - Described herein are methods and pharmaceutical formulations for treating dry eye disease. | 2022-07-28 |
20220233529 | COMBINATION THERAPY COMPRISING A2A/A2B INHIBITORS, PD-1/PD-L1 INHIBITORS, AND ANTI-CD73 ANTIBODIES - Disclosed are combination therapies comprising administration of a CD73 inhibitor, an adenosine A2A or A2B receptor inhibitor, and a PD-1/PD-L1 inhibitor. The disclosed combination therapies are useful in the treatment of diseases related to the activity of adenosine receptors and/or CD73 and/or PD-1/PD-L1 including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases. Anti-CD73 antibodies, PD-1/PD-L1 inhibitors, and A2A/A2B inhibitors are also disclosed. | 2022-07-28 |
20220233530 | INTERMITTENT DOSING OF MDM2 INHIBITOR - The present disclosure relates to mdm2 inhibitors for use in specific dosing schedules. It was found that if sufficiently potent or, in alternative, sufficiently high dose of a Mdm2 inhibitor is used, it can cause antineoplastic effect by triggering much longer lasting antiproliferative mechanism in cells. The long lasting effect can sustain for several weeks after a single dose, which eliminates the need for daily treatment and allows administering the Mdm2i intermittently. A treatment with the intermittent dosing schedule of a Mdm2 inhibitor can be combined with a daily treatment of the Mdm2i or with another pharmaceutically acceptable ingredient. | 2022-07-28 |
20220233531 | ADMINISTRATION OF SUMO-ACTIVATING ENZYME INHIBITOR AND CHECKPOINT INHIBITORS - The present disclosure provides methods, pharmaceutical compositions, and kits for treating cancer in patients in need thereof. The methods comprise administering to a patient in need a small ubiquitin-like modifier (SUMO) activating enzyme (SAE) inhibitor, such as [(1R,2S,4R)-4-{[5-({4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate or a pharmaceutically acceptable salt, in combination with one or more checkpoint inhibitors. Also provided are medicaments for use in treating cancer. | 2022-07-28 |
20220233532 | FAST DISSOLVING PHARMACEUTICAL COMPOSITIONS - The present disclosure relates to the field of pharmaceutical compositions. Furthermore, the present invention relates to an immediate release pharmaceutical composition in the form of a non-effervescent tablet composition comprising dasatinib and a gas generating agent. | 2022-07-28 |
20220233533 | METHODS FOR TREATING LYMPHOMA - Compositions and methods for treating lymphoma, in particular, T-cell lymphoma and follicular lymphoma, in a human patient are provided. The methods entail administering to the patient an effective amount of cerdulatinib. | 2022-07-28 |
20220233534 | CERDULATINIB-CONTAINING TOPICAL SKIN PHARMACEUTICAL COMPOSITIONS AND USES THEREOF - Embodiments described herein are directed to topical compositions for administering cerdulatinib or a pharmaceutically acceptable salt, hydrate or solvate thereof. Embodiments described herein are also directed to methods for preparing the topical compositions. The disclosed compositions are suitable for the treatment of dermatologic conditions such as atopic dermatitis, cutaneous lupus, lichen planus, cutaneous graft versus host disease, contact dermatitis, psoriasis, rosacea, scleroderma, morphea and dermatomyositis. | 2022-07-28 |
20220233535 | USE OF INHIBITORS OF YAP/TAZ FOR THE TREATMENT OF CANCER - Methods of treating or preventing cancer, or treating or preventing noncancerous tumors or lesions, in a subject in need thereof. The methods involve administering a therapeutically effective amount of one or more inhibitors of the YAP/TAZ pathway to the subject. In addition, methods of inhibiting or preventing glycolysis in cancer cells in a subject, promoting mitochondrial respiration in cancer cells in a subject, and promoting oxidative stress in cancer cells in a subject, by administering a therapeutically effective amount of one or more inhibitors of the YAP/TAZ pathway to the subject. | 2022-07-28 |
20220233536 | METHODS OF TREATING CHOLANGIOCARCINOMA - Provided herein are methods of treating advanced or metastatic cholangiocarcinoma in a patient by administering to the patient infigratinib or a pharmaceutically acceptable salt thereof, wherein the patient has progression of the cholangiocarcinoma after previous administration of another therapy. | 2022-07-28 |
20220233538 | METHOD FOR TREATING IDIOPATHIC PULMONARY FIBROSIS - A method for preventing, alleviating and/or treating idiopathic pulmonary fibrosis, which comprises administering an effective amount of a compound represented by formula (I), or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite or prodrug thereof to an individual in need thereof. | 2022-07-28 |
20220233539 | COMPOSITIONS AND METHODS FOR INHIBITING HEDGEHOG PATHWAY - The present invention relates to the use of compositions and methods for treating or preventing a cancer condition in a subject. The use of composition comprises methods of treating or preventing cancer with agents that inhibit Hedgehog pathway activity. The pharmaceutical composition will further comprise agents that inhibit Smoothened receptor and/or Gli transcription in a subject. | 2022-07-28 |
20220233540 | COMPOSITIONS AND METHODS FOR INHIBITING TCF/LEF TRANSCRIPTIONAL ACTIVITY - The present invention relates to the use of compositions for treating or preventing a cancer condition in a subject. The use of composition comprises methods of treating or preventing cancer with agents that inhibit TCF/LEF activity. The pharmaceutical composition will further comprise agents that inhibit TCF/LEF activity in a subject. | 2022-07-28 |
20220233541 | PYRUVATE KINASE MODULATORS AND USE THEREOF - Described herein are methods of using compounds of Formula (I) to modulate PKM2 activity in a subject. These compounds are represented by Formula (I): | 2022-07-28 |
20220233542 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING HUMAN IMMUNODEFICIENCY VIRUS ASSOCIATED PULMONARY ARTERIAL HYPERTENSION - Provided herein are compositions comprising one or more statins and one or more antiretroviral agents, as well as therapeutic or prophylactic treatment methods featuring such combinations. The described compositions and methods are beneficial for treating or preventing human immunodeficiency virus (HIV)-associated pulmonary arterial hypertension (PAH), related conditions, and the symptoms thereof. | 2022-07-28 |
20220233543 | COMPOSITIONS AND METHODS FOR MONITORING, DIAGNOSIS, DETECTION AND TREATMENT OF CANCER - The present invention relates to the use of compositions and methods for treating or preventing a cancer condition in a subject. The use of composition comprises methods of treating or preventing cancer with agents that inhibit Hedgehog pathway activity. The pharmaceutical composition will further comprise agents that inhibit Smoothened receptor and/or Gli transcription in a subject. | 2022-07-28 |
20220233544 | TREATMENTS FOR SKIN CONDITIONS - Compositions and methods for treating skin lesions using topically administered JAK/STAT inhibitors for treating skin lesions and disease such as bullous pemphigoid, bullous impetigo, bullous lichen planus, lichen planus of the mucosa, and the like. | 2022-07-28 |
20220233545 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF - The disclosure relates to compounds that act as an allosteric inhibitors of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the compounds; and methods of treating or preventing kinase-mediated disorders, including cancer and other proliferation diseases. | 2022-07-28 |
20220233546 | Neurologist Formulated Nocturnal Nootropic Founded on a Novel Theory of Brain Aging - Twelve evidence-based hypotheses form the theory of brain aging, herein referred to as Brain Theory. Herein proposed are bioactive, neuro-available substances that, in coaction, work duly to mitigate specific molecular mechanisms of brain aging and enhance cognitive function based on a respective Brain Theory hypothesis. | 2022-07-28 |
20220233547 | CELL ACTIVATOR OF ANIMAL CELL - A cell activator of an animal cell that includes 3H-imidazo[4,5-d][1,2,3]triazine-4,6(5H,7H)-dione. | 2022-07-28 |
20220233548 | METHOD OF TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) - The invention comprises a method for treatment of ADHD or ADHD-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity. | 2022-07-28 |
20220233549 | METHOD FOR ALPHAVIRUS INHIBITION - Described herein are compounds that are useful in treating an alphavirus infection. In some embodiments, the alphavirus is the Chikungunya virus. | 2022-07-28 |
20220233550 | PARP INHIBITOR PELLET PREPARATION AND PREPARATION PROCESS THEREFOR - The present invention relates to a PARP inhibitor pellet composition and a preparation process therefor. The pellet composition comprises a pellet and an optional additional excipient, with the pellet comprising (1) a pellet core; (2) a drug-containing layer and (3) an optional protective layer, wherein the drug-containing layer contains (a) an active ingredient and (b) a binder; when the composition comprises the protective layer, the protective layer contains (c) a coating material; and the active ingredient is (R)-2-fluoro-10a-methyl-7,8,9,10,10a,11-hexahydro-5,6,7a,11-tetraazacyclohepta[def]cyclopenta[a]fluoren-4(5H)-one, a pharmaceutically acceptable salt thereof and a hydrate thereof. | 2022-07-28 |
20220233551 | COMPOSITIONS AND METHODS FOR USING ANDROGEN SIGNALING INHIBITORS - The present invention relates to the use of compositions for treating or preventing a condition in a subject by inhibiting androgen signaling. The use of composition comprises methods of treating or preventing cancer with agents that inhibit androgen signaling. The pharmaceutical composition will further comprise agents that inhibit Androgen receptor activity, transcription, or expression in a subject. | 2022-07-28 |
20220233552 | Methods and compositions for the treatment of IL13Ra2- overexpressing cancer - The invention relates to methods and compositions for treatment of IL13Rα2-overexpressing cancer, wherein the treatment comprises administering a protein tyrosine phosphatase-1B (PTP1B) inhibitor. | 2022-07-28 |